Do you want to read an article? Please log in or register.
Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection
Macular DiseasesRetinal Diseases
Related content
Macular DiseasesRetinal Diseases
PREDICTORS OF REFRACTORY MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION FOLLOWING INTRAVITREAL BEVACIZUMAB
Retina.
Moon BG, Cho AR, Kim YN, Kim JG
doi: 10.1097/IAE.
Macular DiseasesRetinal Diseases
Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
Br J Ophthalmol.
Gale R, Pikoula M, Lee AY, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Users Group.
doi: 10.1136/bjophthalmol-2020-315836.
Surgery and Intervention
Risk factors for repeated dexamethasone intravitreal implant therapy for macular edema due to treatment-naïve branch retinal vein occlusion
BMC Ophthalmol
Huang YT, Lin CJ, Chen HS, Tien PT, Lai CT, Hsia NY, Lin JM, Chen WL, Tsai YY
doi: 10.1186/s12886-021-01904-8
Macular DiseasesRetinal DiseasesFurther Publications
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.
doi: 10.1001/jamaophthalmol.2021.4395
Glaucoma and Ocular PressureMacular DiseasesRetinal Diseases
Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology
Ophthalmology.
Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD, Bakri SJ
doi: 10.1016/
Retinal Diseases
Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion
JAMA Ophthalmol.
Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal Diseases
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial
Ophthalmol Retina.
Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) Study Group.
doi: 10.1016/j.oret.2019.12.019.
COMMENTED
Retinal Diseases
Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Gale R, Gill C, Pikoula M, Lee AY, Hanson RLW, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Database Users Group.
doi: 10.1136/bjophthalmol-2020-317306
Macular Diseases
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
Clin Exp Ophthalmol.
Spooner K, Fraser-Bell S, Hong T, Chang A
doi: 10.1111/ceo.13636.